Matano, Alessandro
Novartis (Switzerland)
2 papers on CoChat
Most cited papers
- Verified
A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.
Sosman, J. A., Kittaneh, M., Lolkema, M. P. J. K., Postow, M. A., Schwartz, G., Franklin, C., Matano, A., Bhansali, S., Parasuraman, S., & Kim, K. (2014) · Journal of Clinical Oncology
Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management
Cited by 129
- Verified
Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas.
Infante, J. R., Shapiro, G. I., Witteveen, P. O., Gerecitano, J. F., Ribrag, V., Chugh, R., Chakraborty, A., Matano, A., Zhao, X., Parasuraman, S., et al. (2013) · Molecular Cancer Therapeutics
Advanced Breast Cancer TherapiesCancer-related Molecular Pathways
Cited by 16
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free